Statement from JDRF on the FDA authorization of the Insulet Omnipod 5
“Authorization of the Insulet Omnipod 5 is a huge win for the type 1 diabetes (T1D) community. As the first tubeless hybrid closed loop system to receive FDA clearance, this is a critical step forward in making day-to-day life better for people living with the disease.
As part of our mission to improve the lives of those affected by T1D, JDRF has been a leader in artificial pancreas research for more than 15 years and partnered with the U.S. Food and Drug Administration (FDA) to establish regulatory pathways to ensure artificial pancreas technology gets into the hands of people with T1D as quickly as possible.
JDRF research grants supported the development of this algorithm through investigators in the JDRF Artificial Pancreas Consortium, Francis (Frank) Doyle, Ph.D., Eyal Dassau, Ph.D., and Howard Zisser, M.D., and their colleagues at the Sansum Institute (California).
Until we find cures, we will continue to support the development of new technologies and treatments to improve blood sugar management to ensure people with T1D can live healthier and more manageable lives. JDRF is also fighting to ensure people with this disease have more choices and better access to the diabetes management tools that work best for them through our Coverage2Control campaign.”